Furthermore, the identification of additional genes, particularly those within the actin-myosin pathway, that exhibit synthetic lethal interactions with MYH4 holds promise for the discovery and therapeutic exploitation of novel cancer vulnerabilities. Here, MYH4 is linked to cancer.